62,734
edits
Changes
no edit summary
|-
| 2013 || || || Vaccine approval || The United States [[wikipedia:FDA|FDA]] approves influenza vaccine ''Flublok'' ([[wikipedia:Protein Sciences|Protein Sciences]]), developed through recombinant DNA technology.<ref>{{cite web|title=FDA Approves Flublok Quadrivalent Flu Vaccine|url=http://www.medscape.com/viewarticle/870201|website=medscape.com|accessdate=31 May 2018}}</ref> ||
|-
| 2013 || June 7 || {{w|Influenza}} || Vaccine approval || "FDA approved Fluzone (Sanofi Pasteur) as the third quadrivalent influenza vaccine licensed for U.S. use."<ref>{{cite web |title=MEMORANDUM |url=https://www.fda.gov/media/97324/download |website=fda.gov |accessdate=3 June 2020}}</ref> ||
|-
| 2014 || October 29 || Serogroup B meningococcal disease || Vaccine approval || "FDA approved the use of Trumenba in the U.S. to prevent serogroup B meningococcal disease."<ref>{{cite web |title=Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) Division of Epidemiology (DE) |url=https://www.fda.gov/media/111536/download |website=fda.gov |accessdate=3 June 2020}}</ref> ||
